Effects of glucose/insulin perturbations on aging and chronic disorders of aging: The evidence

Journal of the American College of Nutrition

Volumn 16, Issue 5, 1997, Pages 397-403

  Preuss, Harry G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aging; Chronic diseases; Hyperglycemia; Hyperinsulinemia; Insulin resistance

Indexed keywords

AGING; CHRONIC DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; PATHOGENESIS; REVIEW;

AGING; ANIMALS; BLOOD GLUCOSE; CHRONIC DISEASE; ENERGY INTAKE; FREE RADICALS; GLYCOSYLATION; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE;

EID: 0030759137     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.1997.10718704     Document Type: Article

References (90)

1. Breslow L: Prevention and control of noncommunicable diseases. WorldHealth Forum 3:429-431, 1982.
2. Editorial: Massstrategiesof prevention;theswingsandroundabouts. Lancet 2:1256-1257, 1982.
3. Zinunet PZ: Primary preventionof diabetes mellitus. DiabetesCare 11:258-262, 1988.
4. Preuss HO, Lieberman S, Oondal I: Macronutrientsin hypertension. J AmColi Nutr 15:22-33, 1996.
5. Tuomilehto J, Zinunet P, Taylor R, Bennett P, Kankaanapaa J, Wolfe E: A cross sectional ecological analysis of blood pressure and its determinants in eleven Pacific populations. 1AmColi Nutr 8:151-165, 1989.
6. Lindahl O, Lindwall L, Spangberg A, Stenram A, Uckerman PA: A vegans regimen with reduced medication in the treatment of hypertension. Br J Nutr 52:11-20, 1984.
7. Szanto S, Yudkin1: The effects of dietary sucrose on blood lipids, serum insulin, platelet adhesivesness and body weight in human volunteers. Postgrad Med 145:602-607, 1969.
8. Reaven OM: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 90(Suppl):7S-12S, 1991.
9. Reaven OM, Ho H, Hoffman BB. Attenuation of fructose-induced hypertension in rats by exercise training. Hypertension 12:129-132, 1988.
10. Reaven OM, Ho H, Hoffman BB: Somatostatin inhibition offructose-induced hypertension. Hypertension 14:117-120, 1989.
11. Landin K, Tengbom L, Smith U: Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J IntMed 229:181-187, 1991.
12. Lee M-K, Miles PDG, Khoursheed M, Gao K-M, Moosa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994.
13. Nolan H, Ludvik B, Beerdsen P, loyce M, Olefsky I: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engll Med 331:1188-1193, 1994.
14. Garcia MI, McNamara RM, Oordon T, Kannell WB: Morbidity and mortality in diabetics in the Framingham population. Diabetes 3:105-111, 1974.
15. Klein BE, Kline R, Moss SE: blood pressure in a population of diabetic persons diagn osed after 30 yearsof age. Am JPublicHealth 74:336-339, 1984.
16. Monolio TA, Savage PI, Bulke OL, Liu KL, Wagenknecht LA, Sidney S, lacobs DR, Roseman JM, Donahue RP, Oberman A: Association of fasting insulin with blood pressure and lipids in young adults. The CARDIAstudy. Arteriosclerosis 10:430-436, 1990.
17. Kriger DR, Landsberg L: Mechanismsin obesity-related hypertension: role of insulin and catecholamines Am J Hypertens 1:84-90, 1988.
18. Masoroill, McCarter RIM, Katz MS, McMahan CA: Dietaryrestriction alters characteristics of glucose fuel use. J Gerontol 47:B202-B208, 1992.
19. Cerami A, Vlassare H, Brownlee M: Olucose and aging. Sci Am 256:90-96, 1987.
20. Reaven OM: Role of insulin resistance in human disease (banting Lecture 1988). Diabetes 37:1595-1607, 1988.
21. Makita Z, Radoff S, Rayfield IL, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991.
22. Parley PS, Harnett ID: Long-term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 23:311-330, 1994.
23. DeFronzo R: Olucose intolerance and aging. Diabetes Care 4: 493-501, 1981.
24. Fink RI, Kolterman O, Griffin J, Olefsky JM: Mechanismsofinsulin resistance in aging. J Clin Invest 71:1523-1535, 1983.
25. Chen M, Bergman RN, Porte lr D: Insulin resistance and B-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab 67:951-957, 1988.
26. Reaven OM, Chen N, Hollenbeck C, Chen YDI: Effect of age on glucose tolerance and glucose uptake in healthy individuals. J AmGeriatrSoc 37:735-740, 1989.
27. Broughton DL, Taylor RL: Review: deterioration of glucose tolerance with age: The role of insulin resistance, Age and Aging 20:22-1225.
28. Shimokata H, Muller DC, fleg JL, Sorkin J, Ziemba AW, Andres R: Age as independent determinant of glucose tolerance. Diabetes 40:44-51.
29. Dengel DR, Pratley RE, Hagberg JM, Goldberg AP: Impairedinsulin sensitivity and maximal responsiveness in older hypertensive men. Hypertension 23:320-324, 1994.
30. DeFronzo RA, Ferinimmi E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194.
31. Reiser KM: Nonenzymatic glycation of collagen in aging and diabetes. Proceedings of the Society for Experimental Biology and Medicine 33:626-634, 1985.
32. Cerami A: Hypothesis. Glucose as a mediator of aging. JAmGeriatr Soc 33:626-634, 1985.
33. Spencer RP: Life prolongation with dietary restriction: protection of genome and core metabolism and the role of glycosylation. Med Hypoth 40:102-104, 1993.
34. Gallaher DD, Csallany AS, Shoeman DW, Olson JM: Diabetes increases excretion ofurinary malonaldehyde conjugates in rats. Lipids 28:663-666, 1993.
35. Flack JM, Showers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med 91 (Suppl 1A):11S-21S, 1991.
36. Nafziger AN, Herrington DM, Bush TL: Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovasculardisease. Epidemiol Rev 13:267-293, 1991.
37. Nestler JE, Clore IN, Blackard WG: Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 6:3073-3075, 1992.
38. Harman D: Free-radical theory of aging. Ann NY Acad Sciences. 717:1-15, 1994.
39. Cutler RG: Antioxidants and aging. Am J Clin Nutr 53 :373S-379S.
40. Harman D: Role of antioxidant nutrients in aging: overview. Age 18:51-62, 1995.
41. Kehrer JP: Free radicals as mediators of tissue injury and disease. Critical Rev Toxicol 23:21-48, 1993.
42. Haliwell B, Cross CE: Oxygen-derived species: their relation to human disease and environmental stress. Environ Health Perspect 102(Suppl10):5-12, 1994.
43. Aureoma OJ: Nutrition and health aspects of free radicals and antioxidants. Food Chern Toxicol 32:671-683, 1994.
44. Stohs SJ: The role of free radicals in toxicity and disease. FreeRadicals 6:1-24, 1995.
45. Jacques PF: A cross sectional study of Vitamin C intake and blood pressure in the elderly. Int J Vit Nutr Res 62:252-255, 1992.
46. Yoshioka M, Matsushita T, ChurmanY: Inverse association of serum ascorbic acid level and blood pressure on rate of hypertension in male adults aged 30-39 years. Int J Vitam Nutr Res 54:343-347.
47. Solonen IT, Solonen R, Ihanainen M, Parvviainen M, Seppamen R, Kantola M, Seppanen K, Rauramaa R: Blood pressure, dietarry fats, and antioxidants. Am J Clin Nutr 48: 1226-1232, 1988.
48. McCarron DA, Morris CD, Henryk HJ, Stantton JL: Blood pressure and nutrient intake in the United States. Science 224: 13392-1398, 1984.
49. Choi ESK, Jacques PF, Dallal GE, Jacobs RA: Correlation of blood pressure with plasma ascorbic acid. Nutr Res 11:1377-1382, 1991.
50. Cohen I., Feldman EB, Feldman DS, Hames CG: Dietary antioxidants and blood pressure. (Abstract). Am J Clin Nutr 51:512, 1990.
51. Jacques PF: A cross-sectional study of Vitamin C intake and blood pressure in the elderly. Int J Vitam Nutr Res 62:252-255, 1992.
52. Efstratopoulos AD, Voyaki SM: Effects of antioxidants on acute blood pressure response to smoking in normotensives and hypertensives. J Hypertens II(suppl 5):S112-S113, 1993.
53. Oster O, Prellwitz W: Selenium and cardiovascular disease. BioI Trace Elem Res 24:91-103, 1990.
54. Salonen IT: Dietary fats, antioxidants, and blood pressure. Ann Med 23:295-298.
55. Greenburg S, Frishman WH: Co-enzyme QIO: A new drug for cardiovascular disease. J Clin Pharmacol 30:596-608, 1990.
56. Maxwell SRJ: Prospects for the use of antioxidant therapy. Drugs 49:345-361, 1995.
57. Masoro EJ: Assessment of nutritional components in prolongation of life and health by diet. Proc Soc Exper BioI Med 193:31-34, 1990.
58. Hopkin K: Aging in focus: caloric restriction may put brakes on aging. J Natl Instit Health 7:47-50, 1995.
59. Coleman GL, Barthold SW, Osbaldiston GW, Foster SJ, Jonas AM: Pathological changes during aging in barrier-reared Fischer 344 male rats. J Gerontol 32:258-278, 1977.
60. Bertrand HA, Lynd FT, Masoro EJ, Yu BP: Changes in adipose mass and cellularity through the adult life of rats fed ad libitum a lifeprolonging restricted diet. J Gerontol 35:827-835, 1980.
61. Yu BP, Masoro EJ, Murata I, Bertrand HA, Lynd FT: Life span study of SPF Fischer 344 male rats fed ad libitum or restricted diets: longevity, growth, lean body mass, and disease. J Gerontol 37: 130-141, 1982.
62. Yu BP, Masoro EJ, McMahan CA: Nutritional influences on aging of Fischer 344 rats: I. physical, metabolic, and longevity cahracteristics. J Gerontol 40:657-670, 1985.
63. Maeda H, GIeiser CA, Masoro EJ, Murata I, McMahan CA, Yu BP: Nutritional influences on aging of Fischer 344 rats: II. pathology. J Gerontol 40:671-688, 1985.
64. Iwasaki K, GIeiser CA, Masoro EJ, McMahaan CA, Sea EJ, Yu BP: The influence of dietary protein source on longevity of age-related disease processes of Fischer rats. J Geronto 143 :B5-B12, 1988.
65. Masoro EJ, Iwasaki K, Gleiser CA, McMahon CA, Seo EJ, Yu BP: Dietary modulation of the progression of nephropathy in aging rats: an evaluation of the importance of protein. Am J Clin Nutr 49:1217-1227, 1989.
66. Cahan V: New study of caloric restricted rodents shows dramatic reduction of disease and increased life span. NIA Announcement Sept 30, pp 5-7, 1991.
67. McCarty MF: Homologous physiological effects of phenformin and chromium picolinate. Moo Hypoth 41 :316-334, 1993.
68. Evans GW, Meyer LK: life span is increased in rats supplemented with a chromium-pyridine 2 carboxylate complex. Adv Sci Res 1:1923, 1994.
69. Ledvina M, Hodanova M: The effect of simultaneous administration of tocopherol and sunflower oil on the life-span of female mice. Exp Gerontol 15:67-71, 1980.
70. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ: Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 81:739-742, 1991.
71. Ceriello A, Quatraro A, Carella F, Varano R, Giugliano D: Evidence for a possible role ofoxygen free radicals in the abnormal functional arterial vasomotion in insulin dependent diabetes. Diabetes Metabol 16:318-322, 1990.
72. Ferrannini E, Bussigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N EngIJ Med 317:350-357, 1987.
73. Reaven GM, Hoffman BB: A role for insulin in the aetiology and course of hypertension? Lancet ii:435-436, 1987.
74. Fuh MM-T, Shieh S-M, Wu D-A, Chen Y-D, Reaven GM: Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 147:1035-1038, 1987.
75. Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotenssin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. AmJ Hypertens 8:353-357, 1995.
76. Fournier AM, Gadia MT, Kubrusly DB, Skyler JS, Sosenko JM: Blood pressure, insulin, and glycemia in nondiabetic subjects. Am J Med 80:861-864, 1983.
77. Solt VB, Brown MR, Kennedy B, Kolterman O, Ziegler MG: Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Mechanisms and implications for management. JAMA 247:49-52, 1982.
78. Sims EAR, Berchtold P: Obesity and hypertension. Mechanisms and implications for management. JAMA 247:49-52, 1982.
79. Krotkiewski M, Mandroukas K, Sjostrom L, Sullivan L, Wetterquist H, Bjomtorp PI: Effects oflong-term physical training on body fat, metabolism and blood pressure in obesity. Metabolism 28:650-658, 1979.
80. Yudkin J: Sucrose, coronary heart disease, diabetes, and obesity: do hormones provide a link? Am Heart J 115:493-498, 1988.
81. Sower JR: Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J 122:932-935, 1991.
82. Evans GW, Swensen G, Walters K: Chromium picolinate decreases calcium excretion and increases dehydroepiandrosterone (DHEA) in post menopausal women. FASEB J 9:A449, 1995.
83. Nafziger AN, Herrington DM, Bush TL: Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovasculardisease. Epidemiol 13:267-293, 1991.
84. Nestler JE, Beer NA, Jakubowicz J, Beer RM: Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 78:549-554, 1994.
85. Nestler IE, Clore IN, Strauss IF 3rd: The effects of hyperinsuIinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocrinol Metab 64:180-184, 1987.
86. Buffington CK, Pourmotabbed G, Kitabchi AE: Case report: amelioration of insulin resistance in diabetes with dehydroepiandosterone. Am J Med Sci 306:320-324, 1993.
87. Men W: Chromium occurrence and function in biological systems. Physiol Rev 49:165-239, 1969.
88. Barrett-eonnor E, Khaw KT, Yen SSC: A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N EngIJ Med 315:1519-1524, 1986.
89. Reid IR, Evans MC, Cooper GJS, Ames RW, Stapleton J: Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol 265:E655-E659, 1993.
90. Buysschaaert M, Cauwe F, Jamaart J: Proximal femur density in type 1 and 2 diabetic patients. Diabetes Metabol 18:32-37, 1992.